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Abstract
Fragile X syndrome (FXS) is the most common inherited form of mental retardation and a leading
known cause of autism. It is caused by loss of expression of the fragile X mental retardation
protein (FMRP), an RNA-binding protein that negatively regulates protein synthesis. In neurons,
multiple lines of evidence suggest that protein synthesis at synapses is triggered by activation of
group 1 metabotropic glutamate receptors (Gp1 mGluRs) and that many functional consequences
of activating these receptors are altered in the absence of FMRP. These observations have led to
the theory that exaggerated protein synthesis downstream of Gp1 mGluRs is a core pathogenic
mechanism in FXS. This excess can be corrected by reducing signaling by Gp1 mGluRs, and
numerous studies have shown that inhibition of mGluR5, in particular, can ameliorate multiple
mutant phenotypes in animal models of FXS. Clinical trials based on this therapeutic strategy are
currently under way. FXS is therefore poised to be the first neurobehavioral disorder in which
corrective treatments have been developed from the bottom up: from gene identification to
pathophysiology in animals to novel therapeutics in humans. The insights gained from FXS and
other autism-related single-gene disorders may also assist in identifying molecular mechanisms
and potential treatment approaches for idiopathic autism.
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INTRODUCTION
Combining insights obtained from basic biological research with genetic and clinical
findings can paint a detailed picture of the molecular events that result in disease, and
suggest ways these mechanisms can be targeted with corrective interventions. Not
surprisingly, application of such “molecular medicine” approaches to psychiatric and
neurodevelopmental disorders has been slow and difficult owing to the daunting biological
complexity of the brain and the complex genetics that underlie most of these diseases (1, 2).
However, in recent years there have been significant advances in understanding the
pathophysiology of several single-gene disorders of brain development associated with
intellectual impairment and autism (see side-bar “The Promise of Molecular Medicine in
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Brain Disorders” and Figure 1). The encouraging prospects for developing new corrective
treatments based on these insights have generated considerable excitement, particularly in
light of reports that the prevalence of autism spectrum disorders (ASDs) is rising sharply (3).
In this review, we describe recent progress in the study of one of these disorders, fragile X
syndrome (FXS), and discuss the implications of these data for autism and other related
neurodevelopmental disorders.
THE PROMISE OF MOLECULAR MEDICINE IN BRAIN DISORDERS
Understanding the genetic basis of psychiatric and neurological disorders eventually will
lead to insights into how the brain functions differently in these diseases. Understanding
their pathophysiology, in turn, will suggest molecular targets for therapeutic
interventions. This process begins with careful phenotypic stratification of patients
followed by gene-variant discovery efforts. Psychiatry, in particular, faces major
obstacles in applying this strategy because (a) many behavioral disorders fall on a
spectrum, making diagnosis and stratification difficult; (b) there is often a large
contribution of environmental influences to disease progression and outcome; and (c)
most disorders do not have a single major genetic cause but are the result of a plethora of
individual mutations and gene copy number variations (2). Single-gene disorders such as
FXS are therefore particularly valuable as models for more genetically complex disorders
such as autism. Once a disease-associated gene has been identified, animal models of the
disorder can be generated through genetic manipulation to reproduce the underlying
genetic deficits. These animal models enable further study of the cellular, physiological,
and behavioral consequences of aberrant gene expression. It is here that basic
neurobiology research becomes an essential partner in the drug discovery process,
allowing the observations made in animal models to be interpreted in the context of a
vast background of knowledge on brain structure and function. Based on the convergence
of information from these sources, hypotheses can be formulated and tested to generate a
plausible model of disease pathophysiology. This model, in turn, can be used to identify
potential drug targets, which then provide the basis for the development of novel
therapeutic strategies that can finally be validated in clinical trials. Although the causes
vary, many autism spectrum disorders may share pathophysiological mechanisms with
FXS and therefore respond to the same treatments.
MIXING THE STREAMS OF GENETICS AND NEUROBIOLOGY IN FRAGILE X
SYNDROME
Fragile X Syndrome
FXS, originally known as Martin-Bell syndrome (4), was first described in 1943 as an X-
linked form of inherited mental retardation (Figure 2) (5). The first evidence regarding the
molecular origin of FXS was obtained in 1969, when an unusual constriction, or fragile site,
was observed at the end of the X chromosome in several affected individuals (6, 7). It was
not until 1991, however, that the fragile site was mapped to a specific location in the
genome (8). This fragile site coincided with an expanded CGG trinucleotide repeat in the 5′
untranslated region of a novel gene, subsequently named fragile X mental retardation 1
(FMR1). Trinucleotide repeat expansions consisting of >200 CGG repeats were found to
cause hypermethylation of the surrounding sequence, resulting in transcriptional silencing of
FMR1 (for an extensive review of this subject, see Reference 5). In 1993, the protein
encoded by FMR1, fragile X mental retardation protein (FMRP), was characterized and
found to be an RNA binding protein that is expressed predominantly in the brain and testes
(9). Shortly thereafter, an Fmr1 knockout mouse model (Fmr1 KO) was generated, in which
part of the Fmr1 gene was deleted to mimic the loss of FMRP expression seen in FXS (10).
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Since then, these Fmr1 KO mice and other animal models have been extensively
characterized, and in conjunction with further in vitro studies of FMRP function, they have
been instrumental in providing insights into potential roles for FMRP in the brain as well as
the pathophysiology of FXS.
FMRP Function and Loss of Function in FXS
One important clue regarding the function of FMRP came from the observation that it is
associated with polyribosomes, implying a role in the regulation of protein synthesis (11–
13). Early biochemical studies yielded contradictory conclusions regarding the precise
nature of this role (see 14 for a review of the early literature); however, there is now broad
support for the hypothesis that FMRP functions as a translational repressor of target mRNAs
(15–17), as we discuss further below. In addition to its role in regulating protein synthesis,
FMRP has also been implicated in the transport and localization of mRNAs to dendrites and
synapses. The mechanisms by which FMRP may regulate protein synthesis and transport
remain under active investigation, and a detailed discussion of the current state of this field
can be found elsewhere (18, 19).
The observation that FMRP may be linked to the protein synthesis machinery, together with
the fact that both FMRP and mRNA are expressed in the dendrites and dendritic spines of
neurons, suggested that it may play an important role in local protein synthesis at synapses
(18, 19). These findings were of particular interest in light of the increasing evidence linking
local protein synthesis to synapse maturation and synaptic plasticity (20), and it was
hypothesized that loss of FMRP expression might result in disruptions of synaptic structure
and function. Consistent with this notion, one of the most prominent morphological
phenotypes observed in both FXS patients and Fmr1 KO mice is an increase in dendritic
spine density and the presence of abnormally long and tortuous spines (21–23). Cultured
neurons from Fmr1 KO mice mimic this phenotype, displaying an increased number of
structural synapses (24). In addition, loss of FMRP in animal models has also been shown to
affect synaptic plasticity: Fmr1 KO mice show exaggerated forms of long-term depression
(LTD) in hippocampus (17) and cerebellum (25), discussed in further detail below.
Moreover, several groups have reported alterations in long-term potentiation (LTP) in the
cortex and hippocampus of Fmr1 KO mice (26–30). Together, these findings suggested that
the absence of FMRP may alter synaptic plasticity throughout the brain, which may be
important in the pathogenesis of FXS.
Metabotropic Glutamate Receptors and Plasticity
It was shortly after the discovery that FMRP plays a role in protein synthesis that the FXS
field crossed paths with emerging lines of research on metabotropic glutamate receptors and
activity-dependent synaptic plasticity, leading to the discoveries that gave rise to current
therapeutic efforts in FXS (Figure 2).
Metabotropic glutamate receptors (mGluRs) are G protein–coupled receptors that link to
intracellular signaling pathways, including the Gq/PLC pathway [group 1 (Gp1) mGluRs]
and Gi/Go pathways (groups 2 and 3 mGluRs). Their existence was predicted in 1986, when
it was observed that agonists of glutamate receptors, thought to be ion channels exclusively
at the time, could also stimulate phosphatidylinositide (PI) turnover (31). In 1988, the first
mGluR mRNAs were isolated (32), and the first corresponding gene was cloned in 1991
(33). These findings caused a major shift in the way people thought about glutamate as a
neurotransmitter (34), suggesting that it may act as a neuromodulator in addition to its role
in fast excitatory neurotransmission. In 1993, Weiler & Greenough presented the first
evidence that one consequence of activating Gp1 mGluRs, comprising mGluR1 and
mGluR5, is increased protein synthesis at synapses (35).
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The explosion of knowledge about glutamate receptors in the 1980s also made possible the
formulation of detailed hypotheses about how excitatory synapses in the brain are
bidirectionally modified by experience to store information. One powerful in vivo model of
experience-dependent plasticity is the visual cortex. Temporarily degrading image formation
in one eye sets in motion synaptic changes in the visual cortex that render neurons
unresponsive to the deprived eye (36). Various theories of synaptic modification were
developed to account for these and related modifications. The influential BCM theory (37)
posited that the loss of strength of deprived-eye synapses was not caused by the loss of
activity from the deprived retina but rather by the presence of stochastic afferent activity
(registered in the cortex as glutamate release) that no longer correlates with strong
postsynaptic responses. On the basis of this idea and the observation that glutamate-
stimulated PI turnover was exaggerated in visual cortex at the age of maximal plasticity, the
hypothesis was put forth that Gp1 mGluRs might serve as a trigger for synaptic weakening
(38). Homosynaptic LTD, triggered by weak activation of glutamate receptors, was
subsequently discovered in the CA1 region of hippocampus (39), and one type of
homosynaptic LTD was later shown to be triggered by activation of mGluR5 (40–42) and to
require synaptic protein synthesis (43, 44). For a recent detailed review of the molecular
mechanisms underlying mGluR-LTD, see Reference 45.
The mGluR Theory of Fragile X Syndrome
In 1997, while conducting a screen for synaptic mRNAs that are translated in response to
Gp1 mGluR activation, Weiler et al. demonstrated that FMRP is synthesized following
application of the receptor agonist DHPG (dihydroxyphenylglycine) in synaptoneurosomes
(46). As described above, another line of investigation showed that DHPG, acting through
mGluR5, can trigger LTD that requires translation of preexisting mRNA (40, 44). Thus,
FMRP was at the top of the list of candidate proteins that are synthesized in response to
mGluR5 activation to stabilize LTD. The simple hypothesis that FMRP is required for
mGluR-LTD was tested using the Fmr1 KO mouse (17). The results showed, however, that
instead of impaired LTD, there was exaggerated LTD in the Fmr1 KO.
These findings did not fit the prevailing model of the time, in which synaptic protein
synthesis was impeded by the loss of FMRP in FXS (46), nor the hypothesis that FMRP
stabilizes LTD. Rather, the data were consistent with the notion that FMRP, by binding
directly to synaptic mRNAs, functions as a repressor of synaptic protein synthesis (15, 16).
Thus, Huber et al. (17) suggested a model in which FMRP normally serves to limit
expression of LTD by inhibiting mGluR-dependent translation of other synaptic mRNAs
encoding the hypothetical “LTD protein(s).” According to this idea, FMRP synthesis in
response to mGluR5 activation normally serves as an important brake on synthesis of other
proteins—in the absence of FMRP, there is runaway or poorly regulated synaptic protein
synthesis. The hypothesis that cerebral protein synthesis is elevated in FXS was later
confirmed by metabolic experiments in the Fmr1 KO mouse, both in vivo and in vitro (47,
48).
Gp1 mGluRs participate in many brain circuits and serve diverse functions in addition to
LTD. By the end of 2002, there were indications in the literature that some other lasting
consequences of activating mGluR1 and mGluR5 require mRNA translation (49–51),
consistent with the early biochemical finding that mGluR activation stimulates protein
synthesis (35). The realization that many of the symptoms of FXS might plausibly be
explained by excessive protein synthesis downstream of mGluR1/5 led to a formal proposal
entitled “the mGluR theory of fragile X,” which was first publicly presented in 2002 and
published in 2004 (52).
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The mGluR theory made two important predictions that could and would be extensively
tested in future experiments. First, it implied that other consequences of mGluR activation
should be altered in the absence of FMRP. Second, and more significantly, it suggested that
a reduction of mGluR activity might restore normal synaptic protein synthesis in the absence
of FMRP and therefore reverse some mutant phenotypes in FXS. This latter prediction
generated considerable excitement in the FXS field because it hinted at the possibility of a
targeted treatment strategy that did not rely on replacement of the FMRP molecule itself.
Testing the mGluR Theory: Evidence for Altered Consequences of mGluR Activation
Following the original discovery of exaggerated mGluR-LTD, a wave of studies focused on
further investigating this and other mGluR-related phenomena in Fmr1 KO mice. In
agreement with the assumptions of the theory, mGluR1-dependent cerebellar LTD was
observed to be exaggerated in the KO (25), as was mGluR1/5-dependent prolongation of
epileptiform bursts in area CA3 of hippocampus (53). One of the mechanisms underlying
mGluR-LTD is the protein synthesis–dependent loss of surface AMPA (alpha-amino-3-
hydroxy-5-methyl-4-isoxazole-propionate) receptors (43), and it was hypothesized that the
excess LTD in the Fmr1 KO mice might be due to an excess internalization of AMPA
receptors (52). This hypothesis was confirmed using knockdown of FMRP levels by short
interfering RNAs in hippocampal cultures (54).
A particularly striking discovery was that hippocampal mGluR-LTD in the Fmr1 KO mice
no longer requires acute stimulation of protein synthesis at the time of induction, consistent
with the notion that “LTD proteins” are constitutively overexpressed and no longer rate-
limiting for LTD in the KO (55, 56). These findings inspired examination of another
mGluR- and protein synthesis–dependent phenomenon that occurs at the same population of
hippocampal synapses, called LTP priming (30). Priming is an enhancement of LTP that
occurs when Gp1 mGluRs are briefly and weakly stimulated prior to delivery of LTP-
inducing tetanic stimulation (51). Like mGluR-LTD, LTP priming normally requires
mGluR-dependent translation of mRNA in wild-type mice but not in the Fmr1 KO (30).
Because it is not known if “LTP priming proteins” and “LTD proteins” are the same or
different, it is probably better to conceptualize these products of mGluR-stimulated mRNA
translation as “plasticity gating proteins.” These gating proteins are apparently
overexpressed in the Fmr1 KO, leading to diverse consequences.
A number of studies have also investigated the role of signaling pathways downstream of
Gp1 mGluRs in protein synthesis and LTD phenotypes in Fmr1 KO mice. mGluR5
receptors were shown to be less tightly coupled with synapses and Homer scaffolding
proteins in Fmr1 KO mice (57), and the Homer-dependent activation of mTOR (mammalian
target of rapamycin) signaling in response to mGluR5 stimulation was absent altogether
(58). Other groups have reported a slight basal increase in ERK (extracellular signal-
regulated kinase) activity (56), an aberrant mGluR-induced inactivation of ERK (59), a basal
increase in the Akt/mTOR pathway (60) and an excess of PI3K (phosphoinositide 3-kinase)
activity (61). However, many of these signaling alterations appear to be highly dependent on
the experimental preparation and are not observed under all conditions. For example, neither
Akt/mTOR nor ERK signaling pathways were altered in hippocampal slices confirmed to
have increased basal protein synthesis in the Fmr1 KO (62). These data suggest that altered
Akt/mTOR and ERK signaling may not be a cause (but may be a consequence) of aberrant
protein synthesis in Fmr1 KO mice. We favor the hypothesis that the protein synthesis
phenotype is due to hypersensitivity of the mRNA translation machinery to normal levels of
mGluR signaling, rather than hyperactivity of the mGluR signaling pathways themselves
(62). It is likely, however, that the aberrant signaling pathways observed in some
preparations do contribute to Fmr1 KO phenotypes, regardless of whether this is proximal or
distal to excess global protein synthesis.
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Finally, an important line of research has focused on identifying target proteins whose
synthesis is regulated by both mGluR5 and FMRP and that are differentially expressed
basally and/or in response to mGluR stimulation in Fmr1 KO mice. A number of interesting
candidates have been proposed to date, including MAP1B, eEF1A, Arc, CaMKIIα, PSD-95,
SAPAP3, and APP (for recent detailed reviews, see 18, 63). The roles of these candidate
proteins in mGluR-related phenotypes in Fmr1 KO mice are currently under investigation.
Reversal of FXS-Related Phenotypes by Reduction or Antagonism of Gp1 mGluRs
Experiments investigating the effects of mGluR inhibition on phenotypes induced by the
loss of FMRP have two essential benefits: They test the validity of the biological principles
underlying the mGluR theory of fragile X, and they provide information on the potential for
targeting mGluRs as a therapeutic strategy in FXS. Accordingly, a significant body of
literature has emerged on this topic in the past five years.
In an extensive proof-of-principle study, Dolen et al. used a genetic strategy to investigate
the effect of reducing mGluR5 levels on FXS-related phenotypes in Fmr1 KO mice (48).
Mice heterozygous for the Grm5 gene (which encodes mGluR5) were crossed with Fmr1
KO mice, and the resulting 50% reduction in mGluR5 protein levels led to the correction (or
prevention) of 7 out of the 8 FXS-related phenotypes assessed. A significant decrease was
observed in the induction of audiogenic seizures, a model for the epilepsy frequently
observed in FXS patients. In addition, the increase in dendritic spines seen in visual cortex
of Fmr1 KO mice, the increase in protein synthesis in hippocampus, and the increase in total
body weight observed in young Fmr1 KO mice were all reversed. Moreover, the genetic
reduction of mGluR5 corrected the excessive hippocampal LTD and abnormal experience-
dependent plasticity of visual cortex. Finally, the cross rescued an enhanced extinction
phenotype in an inhibitory avoidance paradigm, a mouse model for learning and memory.
The only phenotype not rescued in this study was macroorchidism, suggesting that other
pathways (possibly mGluR1) are involved in the testicular phenotype. Similarly, a genetic
approach was used in a Drosophila model of FXS, in which the Drosophila homolog of the
Fmr1 gene, known as dFmr1 or dfxr1, was disrupted. Using a double KO of dFmr1 and the
only Drosophila mGluR, known as dmGluRA, it was shown that dFmr1 and dmGluRA
pathways converge to regulate multiple phenotypes including glutamate receptor trafficking,
synaptic plasticity, presynaptic ultrastructure, and coordinated motor behavior (64–66).
Based on these observations, the authors concluded that loss of the receptor at least partially
corrects defects caused by impaired translational regulation and vice versa.
The genetic rescue experiments provide essential validation, not only for the theory but also
for the concept that drugs targeting mGluR5 could treat multiple aspects of the disease. The
therapeutic potential of mGluR5 inhibitors has also been investigated on various phenotypes
in FXS animal models. Most of these studies have relied on MPEP [2-methyl-6-
(phenylethynyl)-pyridine], a potent negative allosteric modulator of mGluR5 that crosses the
blood-brain barrier. MPEP has proven to be a critical tool for studying mGluR5 function
(67). In the first study to investigate the effects of pharmacological antagonism, acute
administration of MPEP in Fmr1 KO mice was found to reduce the abnormal response of
these mice in an open field test, an experimental measure commonly used to assess anxiety-
like phenotypes in mouse models (68). In addition, like the genetic rescue, MPEP
significantly reduced the probability of audiogenic seizures in these mice.
Subsequently, other groups have demonstrated that MPEP reverses a large number of
phenotypes in Fmr1 KO mice, including prolonged epileptiform discharges in hippocampal
slices (53), deficits in prepulse inhibition of startle (69), decreased mRNA granule
expression (70), excess protein synthesis in hippocampal slices (62), increased density of
dendritic filopodia in hippocampal cultures (69), and hyperactivity of glycogen synthase
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kinase-3 (71). Similarly, MPEP was able to reverse several phenotypes in dFmr1 mutant
flies, including abnormalities in behavioral and structural measures of courtship-related
learning and memory (72), deficits in olfactory memory (73), and increased embryonic
lethality due to excitotoxicity (74). Finally, one group generated Fmr1 knockdown zebrafish
embryos using the morpholino antisense oligonucleotide technology. By developing these
embryos in medium containing MPEP, the authors were able to reverse disruptions in
neurite morphology in the hindbrain and spinal cord of the embryos, as well as in
craniofacial development (75). Together, these data provide compelling evidence that
manipulating mGluR5 signaling can reverse fragile X–related phenotypes across species,
indicating that mGluR5 may indeed provide a viable target for the treatment of FXS.
It is worth emphasizing that the interaction between FMRP and mGluRs seems to be highly
conserved in evolution, appearing across the phylogenetic tree from invertebrates to
mammals. This interplay between a repressor and an activator of protein synthesis may thus
represent an essential core mechanism by which synaptic plasticity is regulated at
glutamatergic synapses, which in turn may explain how its disruption can cause such
widespread and severe pathological alterations in FXS. This striking degree of evolutionary
conservation also boosts confidence that pharmacological approaches that have been
successful in animals have great potential to succeed in humans.
Limitations of the mGluR Theory
Although a large number of studies have provided evidence in support of the mGluR theory,
not all findings are consistent with the simple notion that excessive mGluR-dependent
protein synthesis and synaptic plasticity in the absence of FMRP accounts for mutant
phenotypes in the Fmr1 KO mouse. For example, some of the proposed FMRP target
proteins do not show the expected basal upregulation in KO mice. The synaptic scaffold
protein PSD-95, in particular, was reported to be downregulated in hippocampus owing to
an alteration in mRNA stability, with mGluR stimulation resulting in stabilization of
PSD-95 mRNA in wild-type but not in KO mice (76). Additionally, in cortex (28) and
amygdala (77), forms of LTP that depend on mGluR5 activation in wild-type mice were
found to be absent, rather than exaggerated, in the KO. Furthermore, it was observed that
MPEP injected once daily for several days during early postnatal development actually
accentuated the immature appearance of dendritic spines imaged in vivo in somatosensory
cortex of KO mice (78).
In interpreting these studies, it is important to distinguish manifestations of an ongoing
excess of mGluR signaling from the manifestations of synaptic development that has been
altered because of elevated mGluR signaling. For example, the absence of mGluR5-
dependent LTP in the cortex could reflect the fact that this LTP mechanism has already been
saturated in vivo as a consequence of exaggerated mGluR5 function during development. In
the case of the amygdala, a substantial deficit in basal transmission was also reported at the
same synapses that showed impaired LTP. Reduced synaptic connectivity might have
caused the defective LTP and might have arisen as a consequence of increased mGluR5-
dependent protein synthesis during the development of amygdala circuitry. These alternative
interpretations will need to be explored before rejecting the relevance of the mGluR theory
to the fragile X LTP phenotypes in cortex and amygdala.
It is also important to understand the limitations of the tools that are available to inhibit
mGluR5 signaling. Most pharmacological studies published to date have relied on the
mGluR5 negative allosteric modulator MPEP. However, MPEP is an extremely short-acting
antagonist in vivo, with maximal receptor occupancy lasting only ~15 min in mouse brain
(79). It is therefore virtually impossible to study the drug’s effect on phenotypes that may
require chronic mGluR5 antagonism during brain development. Single MPEP injections will
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not produce chronic inhibition and will likely cause transient rebound increases in mGluR5
function as the drug wears off. An alternative is the “genetic rescue” approach, implemented
by crossing Grm5 heterozygotes with Fmr1 KO mice (48). This approach can overcome
pharmacokinetic limitations, but only a single “dose” can be tested, namely a 50% reduction
in mGluR5 protein. Novel pharmacological agents with long-lasting pharmacokinetic
properties will be necessary to fully address these issues, and their development is currently
under way.
Although the mGluR theory may withstand the challenges presented by the aforementioned
studies, it nevertheless seems very likely that FMRP has functions that are unrelated to
mGluRs. Accordingly, it will be just as informative to identify phenotypes that are not
corrected by mGluR1/5 antagonism as to investigate those that are, since this distinction
may lead to important mechanistic insights that will further direct the development of
successful therapeutic strategies.
Testing the mGluR Theory in Humans
Encouraged by the exciting findings arising from preclinical research, a number of clinical
trials have been initiated to test the efficacy of compounds directly or indirectly related to
mGluR signaling in treating FXS (80, 81). To date, none of these compounds are
specifically approved for the treatment of FXS, but promising preliminary results have been
obtained.
The first Gp1 mGluR inhibitor to be tested in clinical trials was fenobam, a compound that
was originally developed as an anxiolytic with an unknown molecular target and was
subsequently demonstrated to be a selective mGluR5 antagonist (82). An open-label phase II
clinical trial was recently completed, in which 12 adult patients with FXS received a single
dose of fenobam to assess drug safety, pharmacokinetics, and a small number of cognitive
and behavioral effects. In this trial, fenobam was reported to reduce anxiety and
hyperarousal and to improve prepulse inhibition of startle and accuracy on a continuous
performance task (a measure of sustained attention and impulsivity) in a subset of patients
(80, 83). Although these results are encouraging, it is important to note that the study was
not performed blind and was not placebo controlled. The study also revealed highly variable
plasma levels of fenobam after oral dosing, making this compound problematic as a
potential therapeutic and an inadequate agent to test the mGluR theory in humans.
In another small open-label trial, three young adult patients with FXS were treated with
acamprosate, a drug with mGluR antagonist properties that is approved for maintenance of
abstinence from alcohol (84). In all three patients, acamprosate was associated with
improved linguistic communication and global clinical benefit as assessed by the CGI-I
(clinical global impression-improvement) scale.
New, highly potent and selective mGluR5 negative allosteric modulators have shown
promising results in preclinical studies and are currently in clinical trials in FXS (see
http://www.clinicaltrials.gov). These include STX107 (Seaside Therapeutics, phase I trial
initiated in the United States), AFQ056 (Novartis, phase II trial recently completed in
France, Italy, and Switzerland), and RO4917523 (Hoffman-LaRoche, phase II trial initiated
in the United States). The results of these studies are anxiously awaited, as they clearly
represent the best tests to date of the applicability of the mGluR theory to humans.
In addition to targeting mGluRs directly, another approach to reducing excessive mGluR-
mediated plasticity is to target the signaling pathways downstream or upstream of mGluRs.
This approach is exemplified by the recent interest in lithium, which is already clinically
approved for the treatment of mood disorders. Lithium targets multiple intracellular
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signaling pathways, including phospholipase C and glycogen synthase kinase-3, which have
been linked to Gp1 mGluR signaling and FXS, respectively (71, 85). In a pilot trial on 15
patients with FXS, lithium treatment for two months was found to have positive effects on
behavioral adaptive skills and one cognitive measure (85). A second approach that is
currently in clinical trials aims at reducing the presynaptic release of glutamate and hence
the activation of postsynaptic mGluR5. It has been previously shown that GABA-B receptor
agonists such as baclofen inhibit glutamate release, and baclofen has been shown to reduce
audiogenic seizures in Fmr1 KO mice (86). Based on this information, a placebo-controlled
double-blind phase II study was conducted using arbaclofen (also known as STX209), the
R-isomer of baclofen. This study has been completed and it is anticipated that the results
will soon be available.
Finally, clinical trials are also under way for minocycline, a tetracycline analog that (among
other things) inhibits matrix metalloproteinase-9 (MMP-9). It was previously shown that
levels of MMP-9 are elevated in Fmr1 KO mice, possibly as a consequence of excess
mGluR5 signaling, and that minocycline reverses several phenotypes in these mice (87).
Window of Opportunity for Therapeutic Interventions
An important issue for the design of successful treatment strategies concerns the
developmental time window available for intervention. Mutations such as those underlying
FXS presumably alter the trajectory of normal brain development by disrupting the
mechanisms of activity-dependent circuit formation and plasticity (Figure 3a). The key
question then is whether these alterations are reversible, or whether the aberrant
connectivity, once established, results in a permanent dysfunction that cannot be influenced
by subsequent pharmacological interventions. Given that most neurodevelopmental
disorders are currently not diagnosed until well after the onset of symptoms, this issue will
play an essential role in determining treatment outcomes and the need for newborn screening
to facilitate early intervention.
We can consider several potential scenarios for the efficacy of drugs after symptom onset
(Figure 3b). The most optimistic possibility is that intervention after symptom onset results
in near-complete reversal of associated phenotypes. This scenario is conceivable, e.g., if the
molecular mechanisms affected are required only for acute synapse function or for the
reversible strengthening or weakening of previously existing connections. The pessimistic
scenario is that, following an initial window of opportunity, pharmacological approaches can
no longer alter the course or progression of the disorder. This may occur either because of
large-scale irreversible structural alterations, such as aberrant axonal pathfinding or dendritic
branching, or because the pathogenic molecule no longer plays a role in the later stages of
development or in adulthood. An intermediate, but still hopeful, scenario is that intervention
can slow or prevent progression of symptoms, although it may not fully correct previously
established impairments. At the molecular level, this scenario would be likely if structural
abnormalities occurred locally (e.g., the development of aberrant dendritic spines) and could
be compensated for by local adjustments following drug administration.
It should also be considered that most neurodevelopmental disorders manifest as a complex
combination of symptoms, each of which may involve different molecular mechanisms and
developmental trajectories. Moreover, not all individuals with a given disorder will always
express the same combination of symptoms. In order to optimize therapeutic strategies, it
will therefore be necessary to characterize each of these phenotypes individually and
identify the underlying pathogenic mechanisms and developmental time course. Extensive
research in animal models will be crucial in addressing these important questions and should
help guide human clinical trial design.
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MOLECULAR MEDICINE APPROACHES IN OTHER
NEURODEVELOPMENTAL DISORDERS
Although mGluR-based therapeutics for FXS are among the first targeted treatments to
reach clinical trials for any ASD-related disorder, important progress has recently also been
made in other single-gene neurodevelopmental disorders associated with autism (88).
Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC) is a multisystem disorder characterized by tumorous
growths, or hamartomas, in organs including the kidneys, lung, heart, brain, and liver (89).
Clinical manifestations related to the brain can include mental retardation, autism, and
epilepsy. TSC is caused by heterozygous mutations in either the TSC1 or TSC2 gene, both of
which encode proteins that are negative regulators of the mTOR intracellular signaling
pathway. The mTOR pathway has been linked to the control of protein synthesis, and
disruption of this control is thought to underlie the neuropsychiatric phenotypes observed in
TSC.
Mice with a heterozygous mutation in the Tsc2 gene mimic several of the cognitive deficits
observed in human TSC patients. Using this mouse model, it was shown that brief treatment
with rapamycin, an inhibitor of the mTOR complex, rescues deficits in context
discrimination and spatial learning (90). Clinical trials of rapamycin, also known as
sirolimus, are under way in children with TSC, although to our knowledge there are no trials
specifically investigating the effects of rapamycin on the cognitive and behavioral
phenotypes in TSC (http://www.clinicaltrials.gov).
PTEN Mutations
Mutations in the phosphatase and tensin homolog (PTEN) gene, another negative regulator
of the Akt/mTOR signaling pathway, have also been linked to a number of cases of autism
with extreme macrocephaly. A mouse model in which PTEN was deleted in a subset of
neurons in cortex and hippocampus displays neuron hypertrophy resulting in disruptions of
hippocampal structure, as well as increased susceptibility to seizures and increased anxiety
(91). Chronic (four- to six-week) administration of rapamycin was able to reverse all of
these phenotypes in the mice, again suggesting that mTOR might be a relevant drug target
for certain forms of autism (91). Since PTEN mutations are also associated with a greatly
increased susceptibility to certain cancers, clinical trials are currently under way to examine
the effects of rapamycin on tumor growth in cancer patients with PTEN mutations
(http://www.clinicaltrials.gov). However, studies to examine the effects of rapamycin on the
cognitive and behavioral deficits associated with PTEN mutations have yet to be initiated.
Neurofibromatosis Type 1
Neurofibromatosis type 1 (NF1) is a neurodevelopmental disorder associated with cognitive
impairments, including difficulties with visuospatial skills and executive function, as well as
an increased incidence of autism (88, 92). NF1 is caused by mutations in the gene encoding
neurofibromin, which inhibits p21Ras function. Mice with a heterozygous deletion of the
Nf1 gene show an increase in the phosphorylation of ERK1/2, one of the downstream targets
of p21Ras signaling, as well as deficits in visuospatial attention, spatial learning, prepulse
inhibition, and hippocampal LTP (92). Brief administration of the farnesyl transferase
inhibitor lovastatin, which (among other things) decreases p21Ras activity by blocking its
farnesylation and membrane association, was able to reverse all of these phenotypes,
indicating that lovastatin may be a viable treatment for NF1. Clinical trials to investigate the
effects of lovastatin on visual spatial learning and memory in children with NF1 have been
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initiated (http://www.clinicaltrials.gov), although it should be noted that simvastatin, a
related farnesyl transferase inhibitor, was previously found to have no effect on cognitive
functioning in children with NF1 (93).
Rett Syndrome
Rett syndrome (RTT) is a severe ASD that also includes intellectual disabilities as well as
motor symptoms such as ataxia, dystonia, and respiratory dysfunction (88, 94). RTT is
caused by mutations of the X-chromosomal gene encoding the transcriptional regulator
MeCP2, and deletion of this gene in mice causes a severe neurological phenotype related to
the symptoms observed in RTT patients, including gait abnormalities, respiratory
dysfunction, hind limb clasping, and decreased survival. Two recent studies have sought to
reverse these phenotypes using a genetic and a pharmacological strategy, respectively. In the
former, MeCP2 function was restored during or following onset of symptoms using a
tamoxifen-inducible Cre-LoxP strategy, resulting in the robust reversal of several associated
phenotypes (94). This is an extremely important proof of principle that the course of this
disease can be arrested and even reversed with manipulations begun in late adolescence (the
optimistic scenario in Figure 3). In the second study, mice were treated with insulin-like
growth factor 1 (IGF-1), based on previous observations that another growth factor, brain-
derived neurotrophic factor (BDNF), was a key target of MeCP2 regulation (95). IGF-1
administration improved several phenotypes in the MeCP2 KO mice, including locomotor
activity, respiratory function, dendritic spine density, and survival. Neither of these rescue
strategies has resulted in the initiation of clinical trials to date, but they suggest that the
development of targeted treatments for RTT may be a feasible goal in the future.
Idiopathic Autism
In addition to the providing the basis for the development of targeted treatments for specific
developmental disorders, the above studies are also yielding key insights into related
disorders for which few mechanistic details are currently available. Idiopathic autism has
been notoriously difficult to study owing to the lack of suitable animal models. By
comparing the molecular mechanisms underlying different single-gene disorders, it may be
possible to discover commonalities and general principles that might hold true even for
those cases in which no specific genetic cause has been identified. One such key principle
arose from the observation that many of the single-gene disorders appear to affect key
regulators of protein synthesis, suggesting that it may be the dysregulation of protein
synthesis itself that represents one final common pathogenic mechanism (96). According to
this theory, aberrant synaptic protein synthesis caused by mutations or copy-number
variations in regulatory signaling pathways may lead to changes in synaptic connectivity and
function, which subsequently result in the cognitive and behavioral deficits that are observed
in ASDs. This notion has recently been supported by clinical studies linking autism to
mutations in the gene encoding the translation initiation factor eIF4E (97) and to copy-
number variations in GTPase/Ras signaling pathways (98) that may be involved in the
regulation of synaptic protein synthesis. Based on these findings, treatments that
successfully target protein synthesis pathways in the single-gene disorders mentioned above,
including mGluR5 modulators, may very well have broader therapeutic applications in
idiopathic autism.
However, it is also clear that altered synaptic protein synthesis is not the only mechanism by
which autism-related mutations can cause abnormalities in synaptic function. For example, a
key role is also emerging for mutations in structural proteins that are involved in synaptic
development or function, including the synaptic cell adhesion molecules neuroligin-3,
neuroligin-4 and neurexin-1, and the synaptic scaffolding protein SHANK3 (for recent
detailed reviews, see 99–101). While structural proteins themselves are unlikely to represent
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useful targets for traditional small-molecule drug therapies, it may ultimately be possible to
target common downstream consequences of these mutations, such as a shift in the balance
of excitatory and inhibitory synaptic transmission. Indeed, the first studies investigating such
strategies in mouse models are beginning to emerge (102), although significant further pre-
clinical research is likely to be necessary before clinical trials can be considered.
It is already clear that diverse molecular mechanisms can contribute to the synaptic
abnormalities that underlie ASDs. In order to design appropriate therapeutic strategies for
idiopathic autism, it will be critical to identify biomarkers that report the pathophysiological
processes at work in the brains of the affected individuals.
FUTURE ISSUES
1. Is it possible to identify additional novel therapeutic targets for FXS based on
insights into the molecular mechanisms of FMRP function at the synapse? Can
these targets be validated in animal models of FXS and subsequently in clinical
trials?
2. What is the developmental window of opportunity for the pharmacological
treatment of FXS? Can existing symptoms be corrected or improved, or is it
necessary to initiate treatment early in pre- or postnatal development prior to
phenotype onset? Is newborn screening for early intervention warranted?
3. Can we gain new insights into idiopathic autism from comparing and
contrasting the molecular mechanisms underlying different autism-associated
single-gene disorders? Can this knowledge be used to develop novel treatment
strategies for at least a subset of individuals with ASDs?
4. What peripheral biomarkers will best reflect brain pathophysiology and inform
clinical trials and treatments for autism of unknown etiology?
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ASD autism spectrum disorder
FXS fragile X syndrome
FMRP fragile X mental retardation protein
LTD long-term depression
mGluR metabotropic glutamate receptor
TSC tuberous sclerosis complex
NF1 neurofibromatosis type 1
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Figure 1.
The promise of molecular medicine in psychiatric and neurodevelopmental disorders (see
sidebar “The Promise of Molecular Medicine in Brain Disorders” for explanation).
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Figure 2.
Some milestones in defining the pathophysiology of fragile X syndrome (FXS). The current
therapeutic efforts in FXS originate from the mixing of two independent lines of research:
genetic research on FXS (left timeline, yellow) and basic neurobiology research on mGluR-
dependent synaptic plasticity (right timeline, blue). The discovery that mGluR-LTD is
exaggerated in Fmr1 knockout (KO) mice (17) led to the mGluR theory of FXS
pathophysiology, culminating in the initiation of clinical trials to test the efficacy of
mGluR5 antagonists in the treatment of FXS. Numbers in parentheses are reference
citations. Fmr1, fragile X mental retardation 1; FMRP, fragile X mental retardation protein;
mGluR, metabotropic glutamate receptor; LTD, long-term depression; MPEP, 2-methyl-6-
(phenylethynyl)-pyridine.
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Figure 3.
Prospects for the treatment of a developmental brain disorder. (a) Divergence of brain
maturation in normal development versus development in fragile X syndrome (FXS). This
continuous divergence results in an accumulated deficit in individuals with FXS that
increases with age. (b) Prospects for treatment of this accumulated deficit in FXS. Three
scenarios are conceivable with respect to interventions that occur following symptom onset:
(i ) The optimistic view assumes that pharmacological intervention after symptom onset
results in near-complete reversal of associated phenotypes. (ii ) The pessimistic view is that
after an initial window of opportunity, pharmacological approaches can no longer alter the
course of the disorder. (iii ) The intermediate (but still hopeful) view suggests that
pharmacological intervention can slow or prevent progression of symptoms, although it may
not fully correct previously established impairments.
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